Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Niagen Bioscience (NAGE) over the last 16 years, with Q3 2025 value amounting to $4.6 million.

  • Niagen Bioscience's Net Income towards Common Stockholders rose 14377.0% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 127569.02%. This contributed to the annual value of $8.5 million for FY2024, which is 27314.7% up from last year.
  • Latest data reveals that Niagen Bioscience reported Net Income towards Common Stockholders of $4.6 million as of Q3 2025, which was up 14377.0% from $3.6 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Net Income towards Common Stockholders high stood at $7.2 million for Q4 2024, and its period low was -$8.9 million during Q3 2021.
  • In the last 5 years, Niagen Bioscience's Net Income towards Common Stockholders had a median value of -$1.4 million in 2022 and averaged -$1.5 million.
  • Per our database at Business Quant, Niagen Bioscience's Net Income towards Common Stockholders crashed by 11010.68% in 2021 and then surged by 2416000.0% in 2025.
  • Niagen Bioscience's Net Income towards Common Stockholders (Quarter) stood at -$5.3 million in 2021, then soared by 72.88% to -$1.4 million in 2022, then soared by 107.89% to $114000.0 in 2023, then soared by 6197.37% to $7.2 million in 2024, then tumbled by 36.23% to $4.6 million in 2025.
  • Its Net Income towards Common Stockholders stands at $4.6 million for Q3 2025, versus $3.6 million for Q2 2025 and $5.1 million for Q1 2025.